197 related articles for article (PubMed ID: 37415222)
1. Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models.
Zhang H; Du Y; Qi L; Xiao S; Braun FK; Kogiso M; Huang Y; Huang F; Abdallah A; Suarez M; Karthick S; Ahmed NM; Salsman VS; Baxter PA; Su JM; Brat DJ; Hellenbeck PL; Teo WY; Patel AJ; Li XN
J Transl Med; 2023 Jul; 21(1):444. PubMed ID: 37415222
[TBL] [Abstract][Full Text] [Related]
2. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.
Liu Z; Zhao X; Mao H; Baxter PA; Huang Y; Yu L; Wadhwa L; Su JM; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Hurwitz RL; Lau CC; Chintagumpala M; Blaney SM; Li XN
Neuro Oncol; 2013 Sep; 15(9):1173-85. PubMed ID: 23658322
[TBL] [Abstract][Full Text] [Related]
3. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.
Yu L; Baxter PA; Zhao X; Liu Z; Wadhwa L; Zhang Y; Su JM; Tan X; Yang J; Adesina A; Perlaky L; Hurwitz M; Idamakanti N; Police SR; Hallenbeck PL; Blaney SM; Chintagumpala M; Hurwitz RL; Li XN
Neuro Oncol; 2011 Jan; 13(1):14-27. PubMed ID: 21075780
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate.
Chen Q; Wu J; Ye Q; Ma F; Zhu Q; Wu Y; Shan C; Xie X; Li D; Zhan X; Li C; Li XF; Qin X; Zhao T; Wu H; Shi PY; Man J; Qin CF
mBio; 2018 Sep; 9(5):. PubMed ID: 30228241
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
6. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma.
Spencer D; Yu D; Morshed RA; Li G; Pituch KC; Gao DX; Bertolino N; Procissi D; Lesniak MS; Balyasnikova IV
Theranostics; 2019; 9(7):2071-2083. PubMed ID: 31037157
[TBL] [Abstract][Full Text] [Related]
8. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
[TBL] [Abstract][Full Text] [Related]
9. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
[TBL] [Abstract][Full Text] [Related]
10. Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors.
Qi L; Kogiso M; Du Y; Zhang H; Braun FK; Huang Y; Teo WY; Lindsay H; Zhao S; Baxter P; Zhao X; Yu L; Liu Z; Zhang X; Su JM; Adesina A; Yang J; Chintagumpala M; Perlaky L; Tsz-Kwong Man C; Lau CC; Li XN
Cancer Lett; 2020 Nov; 493():197-206. PubMed ID: 32891713
[TBL] [Abstract][Full Text] [Related]
11. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
Nakashima H; Nguyen T; Kasai K; Passaro C; Ito H; Goins WF; Shaikh I; Erdelyi R; Nishihara R; Nakano I; Reardon DA; Anderson AC; Kuchroo V; Chiocca EA
Clin Cancer Res; 2018 Jun; 24(11):2574-2584. PubMed ID: 29511029
[No Abstract] [Full Text] [Related]
12. The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma.
Bhat K; Saki M; Vlashi E; Cheng F; Duhachek-Muggy S; Alli C; Yu G; Medina P; He L; Damoiseaux R; Pellegrini M; Zemke NR; Nghiemphu PL; Cloughesy TF; Liau LM; Kornblum HI; Pajonk F
Proc Natl Acad Sci U S A; 2020 May; 117(20):11085-11096. PubMed ID: 32358191
[TBL] [Abstract][Full Text] [Related]
13. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
[TBL] [Abstract][Full Text] [Related]
14. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.
Kurokawa C; Iankov ID; Anderson SK; Aderca I; Leontovich AA; Maurer MJ; Oberg AL; Schroeder MA; Giannini C; Greiner SM; Becker MA; Thompson EA; Haluska P; Jentoft ME; Parney IF; Weroha SJ; Jen J; Sarkaria JN; Galanis E
J Natl Cancer Inst; 2018 Oct; 110(10):1123-1132. PubMed ID: 29788332
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence.
Oudin A; Moreno-Sanchez PM; Baus V; Niclou SP; Golebiewska A
BMC Cancer; 2024 Jan; 24(1):3. PubMed ID: 38166949
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma.
Xiao J; Liang J; Fan J; Hou P; Li X; Zhang H; Li K; Bu L; Li P; He M; Zhong Y; Guo L; Jia P; Xiao Q; Wu J; Peng H; Li C; Xing F; Guo D
Cancer Res; 2022 Sep; 82(18):3359-3374. PubMed ID: 35792620
[TBL] [Abstract][Full Text] [Related]
17. Cell Membrane-Coated Oncolytic Adenovirus for Targeted Treatment of Glioblastoma.
Jia X; Wang L; Feng X; Liu W; Wang X; Li F; Liu X; Yu J; Yu B; Yu X
Nano Lett; 2023 Dec; 23(23):11120-11128. PubMed ID: 38032110
[TBL] [Abstract][Full Text] [Related]
18. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
[TBL] [Abstract][Full Text] [Related]
20. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Mantwill K; Naumann U; Seznec J; Girbinger V; Lage H; Surowiak P; Beier D; Mittelbronn M; Schlegel J; Holm PS
J Transl Med; 2013 Sep; 11():216. PubMed ID: 24044901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
